Christine Chavany

Dr Chavany has led Milagen’s R&D effort in cancer biomarker discovery and development since the inception of the company in 1997. She has been a key figure in the development of all company’s technologies, from antibody screening to biomarker discovery, from monoclonal antibody production to immunoassay development. Dr. Chavany has also been a Principal Investigator in numerous NIH-SBIR-funded projects.

Dr. Chavany oversees the GMP manufacturing of Milagen diagnostic product pipeline and provides guidance in regulatory affairs and compliance, closely working with the Regulatory Team.

Dr. Chavany received her Ph.D. in Pharmaceutical Sciences from the University of Paris XI-Orsay in 1991 and trained at the National Cancer Institute of the NIH from 1991 to 1997 focusing on the anti-cancer activity of antisense oligonucleotides and drugs, and characterization of transgenic mice as a model for neurodegenerative diseases. Prior to joining Milagen, she held Scientist positions in the biotech sector. Dr. Chavany is a member of the American Association for Cancer Research (AACR) and is Regulatory Affair Certified by the Regulatory Affair Professional Society since 2001.